Shanghai Henlius Biotech (HKG:2696) dosed the first patient in a phase 1 study of Ipilimumab biosimilar HLX13 in the U.S., according to a Thursday Hong Kong bourse filing.
The drug has been developed by the company as first-line treatment for patients with unresectable advanced hepatocellular carcinoma.
Jiangsu Lopal Tech. Group (SHA:603906, HKG:2465) said there were no undisclosed matters that would warrant an unusual movement in its stock's price, according to a Hong Kong bourse filing Wednesday.Shares of the automotive specialty chemicals seller were down nearly 6% in Thursday late morning trade.On Wednesday, its shares rose 2% at close, snapping a three-day streak of losses.
Ernst & Young expects 84 initial public offerings in Hong Kong during the first half of 2026, raising a combined HK$209.8 billion, a five-year high, the audit firm said in its Chinese mainland and Hong Kong IPO report released Wednesday.The company noted a 100% increase in the number of IPOs and a 92% jump in funds raised in H1 2026 from the same period last year.A-share firms remained a key driver of the Hong Kong IPO market, with 121 mainland-listed companies applying for Hong Kong listings as of June 23.Industrial and technology companies accounted for 65% of IPO deals and 74% of total proceeds. These sectors mostly comprise segments such as AI large models and semiconductor chips, according to the report.
Samsung Electronics (KRX:005930) denied media rumors of the company planning to repurchase 90 trillion won worth of shares over a period of three years, beginning in July, according to a Thursday filing with the Korea Exchange.Denying the report published by Munhwa Ilbo in a Wednesday news report, Samsung Electronics said that although it was reviewing a share repurchase plan for stock-based compensation based on its 2026 management performance, no key matters, including the schedule or scale of the repurchase, had been finalized.Shares of the company rose nearly 5% in recent trade.